{"id":"W4400037535","doi":"10.1200/jco.2024.42.16_suppl.8522","title":"Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced <i>ROS1</i> fusion-positive (<i>ROS1+)</i> NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; ROS1; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Clinical trial; Oncology; Cancer research; Cancer; Adenocarcinoma; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001432814,0.0003864407,0.0008036826,0.000224082,0.0001697945,0.0006593984,0.0002649396,0.0003768099,0.001922917],"category_scores_gemma":[0.0006775687,0.0001543235,0.0007279772,0.0002980883,0.0002501321,0.0005329857,0.0002694013,0.001163872,0.0004836586],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007177219,"about_ca_system_score_gemma":0.0005542796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004199985,"about_ca_topic_score_gemma":0.002234923,"domain_scores_codex":[0.9996233,0.00014949,0.00003615357,0.00007557253,0.00006529955,0.00005018393],"domain_scores_gemma":[0.9996045,0.00006249508,0.0001905234,0.00002066332,0.00003230067,0.00008949704],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3145506,0.01117378,0.0759336,0.00366389,0.004023494,0.0003952495,0.0004132236,0.00473589,0.05786848,0.0005007918,0.0221274,0.5046135],"study_design_scores_gemma":[0.2210015,0.4119976,0.292609,0.0005727117,0.006066393,0.002617694,0.0002662229,0.005753666,0.02181184,0.0009055979,0.03626705,0.0001307106],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739155,0.01646117,0.0007011963,0.0008605829,0.0001046783,0.001007317,0.002006285,0.00009328737,0.004849912],"genre_scores_gemma":[0.9884776,0.004621132,0.0009466276,0.0008578558,0.0001147369,0.0004934433,0.002949905,0.00001538656,0.001523167],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001922917,"threshold_uncertainty_score":0.007577598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05621043796304222,"score_gpt":0.4526069453941379,"score_spread":0.3963965074310957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}